Cargando…

Effect of baseline cancer pain on the efficacy of immunotherapy in lung cancer patients

BACKGROUND: Cancer pain is a common symptom in cancer patients. However, few reports have evaluated the effect of baseline cancer pain on the efficacy of immunotherapy in lung cancer patients. The aim of this retrospective study is to reveal the effect of baseline cancer pain on the prognosis of lun...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Huan, Wei, Jingwen, Sun, Wei, Song, Zhengbo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482640/ https://www.ncbi.nlm.nih.gov/pubmed/37691656 http://dx.doi.org/10.21037/jtd-23-375

Ejemplares similares

Sequential therapy with crizotinib and a second-generation ALK inhibitor versus direct therapy of a second-generation ALK inhibitor in ALK-positive advanced lung cancer: a real-world study
por: Wei, Jingwen, et al.
Publicado: (2023)

Baseline anemia predicts a poor prognosis in patients with non-small cell lung cancer with epidermal growth factor receptor mutations: a retrospective study
por: Wei, Jingwen, et al.
Publicado: (2022)

Efficacy and safety of immune checkpoint inhibitors in lung large-cell neuroendocrine carcinoma
por: Shi, Zheng, et al.
Publicado: (2023)

Effects of intrapericardial administration after catheter drainage on malignant pericardial effusion in non‐small cell lung cancer: A real‐world study
por: Wei, Jingwen, et al.
Publicado: (2023)

Baseline anemia and anemia grade are independent prognostic factors for stage IV non-small cell lung cancer
por: Chen, Cheng, et al.
Publicado: (2021)

Efficacy of gefitinib or erlotinib in patients with squamous cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2013)

The efficacy and safety of anlotinib treatment for advanced lung cancer
por: Shao, Lan, et al.
Publicado: (2019)

Immune checkpoint inhibitors beyond first-line progression with prior immunotherapy in patients with advanced non-small cell lung cancer
por: Xu, Manyi, et al.
Publicado: (2023)

Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study
por: Wang, Wenxian, et al.
Publicado: (2022)

Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations
por: Chen, Dan, et al.
Publicado: (2016)

The effect of EGFR‐TKIs on survival in advanced non‐small‐cell lung cancer with EGFR mutations: A real‐world study
por: Yu, Xiaoqing, et al.
Publicado: (2022)

Efficacy of chemotherapy plus gefitinib treatment in advanced non-small-cell lung cancer patients following acquired resistance to gefitinib
por: SONG, ZHENGBO, et al.
Publicado: (2013)

Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations
por: Si, Jinfei, et al.
Publicado: (2023)

Efficacy and Safety of High-Dose Controlled-Release Oxycodone in the Treatment of Moderate to Severe Pain in Patients with Advanced Cancer: A Retrospective Study
por: Wang, Wenxian, et al.
Publicado: (2018)

Analysis of the efficacy and safety of immunotherapy in advanced thymoma patients
por: Hao, Yue, et al.
Publicado: (2022)

Clinical outcomes of immune checkpoint inhibitor therapy for advanced lung adenosquamous carcinoma
por: Wei, Jingwen, et al.
Publicado: (2023)

Efficacy of brain radiotherapy plus EGFR-TKI for EGFR-mutated non-small cell lung cancer patients who develop brain metastasis
por: Wang, Wenxian, et al.
Publicado: (2018)

Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy
por: Luongo, C., et al.
Publicado: (2021)

Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy
por: Brilli, L., et al.
Publicado: (2020)

Effect of cyclooxygenase inhibitor use on immunotherapy efficacy in non‐small cell lung cancer
por: Kanai, Osamu, et al.
Publicado: (2021)

T lymphocytes related biomarkers for predicting immunotherapy efficacy in non-small cell lung cancer
por: Wei, Xiaoying, et al.
Publicado: (2021)

The rest period between chemotherapy and immunotherapy influences the efficacy of immune checkpoint inhibitors in lung cancer
por: Kang, Da Hyun, et al.
Publicado: (2022)

Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung Function
por: Pavord, Ian D, et al.
Publicado: (2020)

Immunotherapy for Lung Cancers
por: Ho, Ming-Yi, et al.
Publicado: (2011)

Clinical Efficacy and Future Prospects of Immunotherapy in Lung Cancer
por: Kinoshita, Tomonari, et al.
Publicado: (2021)

Efficacy and safety of immune checkpoint inhibitors (ICIs) combined with antiangiogenic therapy for thymic epithelial tumors (TETs): a retrospective study
por: Xiang, Jing, et al.
Publicado: (2023)

Relationship between Patients' Baseline Characteristics and Survival Benefits in Immunotherapy-Treated Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Hu, Xuanbo, et al.
Publicado: (2022)

The efficacy of pregabalin for the treatment of neuropathic pain in Japanese subjects with moderate or severe baseline pain
por: Parsons, Bruce, et al.
Publicado: (2019)

Treatment and Prognosis of Solid and Cystic Brain Metastases in Patients with Non-Small-Cell Lung Cancer
por: Xu, Yi-Bing, et al.
Publicado: (2021)

Association between baseline C‑reactive protein level and survival outcomes for cancer patients treated with immunotherapy: A meta‑analysis
por: Xu, Yu, et al.
Publicado: (2023)

Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non‐small cell lung cancer patients
por: Song, Peng, et al.
Publicado: (2020)

Microbiota and Lung Cancer. Opportunities and Challenges for Improving Immunotherapy Efficacy
por: Ocáriz-Díez, Maitane, et al.
Publicado: (2020)

Safety and efficacy of microwave ablation for lung cancer adjacent to the interlobar fissure
por: Wang, Nan, et al.
Publicado: (2022)

Salvage treatment with apatinib for advanced non-small-cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2017)

Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer
por: Carbone, Carmine, et al.
Publicado: (2019)

The Role of Gut Microbiota in Lung Cancer: From Carcinogenesis to Immunotherapy
por: Liu, Xiangjun, et al.
Publicado: (2021)

Comparison of Efficacy and Safety of Platinum-Based Chemotherapy as First-Line Therapy between B3 Thymoma and Thymic Carcinoma
por: Hao, Yue, et al.
Publicado: (2022)

Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, C-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy
por: Sung, MinDong, et al.
Publicado: (2023)

Comparison of efficacy and safety of second‐ and third‐generation TKIs for non‐small‐cell lung cancer with uncommon EGFR mutations
por: Hao, Yue, et al.
Publicado: (2023)

Immunotherapy in lung cancer.
por: Al-Moundhri, M., et al.
Publicado: (1998)

Cannot write session to /tmp/vufind_sessions/sess_kfquq5pke6lkjabjleshmnl2ms